RecruitingPhase 3NCT05288179

Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis

Studying Pneumoconiosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing Continent Pharmaceutical Co, Ltd.
Principal Investigator
Huaping Dai, Dr
China-Japan Friendship Hospital
Intervention
Pirfenidone Capsules(drug)
Enrollment
272 target
Eligibility
18-70 years · All sexes
Timeline
2022 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05288179 on ClinicalTrials.gov

Other trials for Pneumoconiosis

Additional recruiting or active studies for the same condition.

See all trials for Pneumoconiosis →

← Back to all trials